SNY Sanofi

By Inti Landauro

PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) on Monday said it will resubmit in the second quarter an application to the U.S. Food and Drug Administration for its multiple sclerosis treatment Lemtrada, which received a negative review in November last year.

Genzyme, the unit of Paris-listed Sanofi which develops Lemtrada--also known as alemtuzumab--will resend an application to the FDA to address all the issues raised by the agency.

Genzyme has decided to resubmit the application instead of appealing the FDA decision as previously announced.

Write to Inti Landauro at inti.landauro@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires